United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

Form 6-K

  

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of October, 2016

 

Commission File Number: 001-35892

  

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x   Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes   ¨   No   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   ¨   No   ¨

 

 

 

  

Other Events

 

On October 26, 2016, GW Pharmaceuticals plc (the “Company”), issued a regulatory news service (“RNS”) announcement setting forth details of a gift of 250,000 ordinary shares par value £0.001per share (“Ordinary Shares”) by Dr Geoffrey Guy, the Company’s Chairman and member of its board of directors to a family member. This RNS is attached as Exhibit 99.1 hereto and is incorporated by reference herein. On October 25, 2016, the Company issued an RNS with details of transactions by its Directors in the Company’s Ordinary Shares and American Depositary Shares. This RNS is attached as Exhibit 99.2 hereto and is incorporated by reference herein. The information contained in Exhibit 99.1 and Exhibit 99.2 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

 

Exhibits    

99.1   Regulatory news service announcement dated October 26, 2016
99.2   Regulatory news service announcement dated October 25, 2016

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
   
  By: /s/ Adam George
  Name: Adam George
  Title: Chief Financial Officer
     
Date: October 26, 2016